DPQ
DPQ Basic information
- Product Name:
- DPQ
- Synonyms:
-
- PARP Inhibitor III, DPQ
- 5-(4-piperidin-1-ylbutoxy)-3,4-dihydro-2H-isoquinolin-1-one
- DPQ
- 3,4-DIHYDRO-5-[4-(1-PIPERIDINYL)BUTOXY]-1(2H)-ISOQUINOLINONE
- 3,4-DIHYDRO-5[4-(1-PIPERIDINYL)BUTOXYL]-1(2H)-ISOQUINOLINE
- 3,4-DIHYDRO-5-[4-(1-PIPERIDINYL)BUTOXYL]-1(2H)-ISOQUINOLINONE
- 3,4-DIHYDRO-5[4-(1-PIPERINDINYL)BUTOXY]-1(2H)-ISOQUINOLINE
- 5-[4-(1-PIPERIDINYL)-BUTYLOXY]-1,2,3,4-TETRAHYDROISOQUINOLIN-1-ONE
- CAS:
- 129075-73-6
- MF:
- C18H26N2O2
- MW:
- 302.41
- Mol File:
- 129075-73-6.mol
DPQ Chemical Properties
- Melting point:
- 107-109°
- Boiling point:
- 528.8±50.0 °C(Predicted)
- Density
- 1.096±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- DMSO: Soluble
- form
- solid
- pka
- 14.54±0.20(Predicted)
- color
- White to off-white
- biological source
- synthetic (organic)
DPQ Usage And Synthesis
Description
The poly(ADP-
Uses
DPQ has been used as a PARP1 (poly(ADP-ribose) polymerase 1) inhibitor in in vivo studies to determine the loss of γ-H2AX (H2A histone family member X) upon irradiation.
Uses
3,4-Dihydro-5-[4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone is a potent inhibitor of poly(ADP-ribose) polymerases, a family of enzymes that plays a crucial role in DNA repair and apoptosis in respons e to reactive oxygen and nitrogen species.
Uses
Reagent for inhibition of PARP.
Biochem/physiol Actions
3,4-Dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) is known to decrease the PARP 1 (poly(ADP-ribose) polymerase 1) mediated apoptosis under the influence of ischemia. It is considered as more effective inhibitor than the traditionally used PARP1 inhibitor 3-aminobenzamide.
in vivo
DPQ (10 mg/kg; intraperitoneal injection; single dose; 6 h) significantly attenuates lung inflammation, neutrophil infiltration, and vascular leakage in LPS-induced acute lung injury model of C57BL/6 mice, inhibiting NF-κB pathway activation[2].
DPQ (10 mg/kg; intraperitoneal injection; single dose; 4 weeks) improves cardiac function and reduced apoptosis and oxidative stress in myocardial infarction model of Wistar rats[3].
| Animal Model: | LPS-Induced Acute Lung Injury Model in C57BL/6 mice (male, 8-10 weeks old) |
| Dosage: | 10 μg/kg (dissolved in 0.01% DMSO (PBS) |
| Administration: | Intraperitoneal injection, 30 min after LPS chanllenge (7.5 mg/kg; ip; single dose) |
| Result: | Reduced neutrophil infiltration (50% decrease), MPO activity (40% decrease), and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in lungs. Restored vascular permeability (Evans blue extravasation reduced by 35%), and inhibited apoptotic cell death (TUNEL-positive cells decreased by 45%). Suppressed NF-κB activation with reduced IkB-α degradation and p65 phosphorylation. |
| Animal Model: | Myocardial Infarction model in Wistar rats (male, 4 months old) via coronary artery ligation[3] |
| Dosage: | 10 mg/kg (dissolved in DMSO) |
| Administration: | Intraperitoneal injection, single dose immediately after MI induction |
| Result: | Improved cardiac function (FS increased by 25%, EDD/ESD reduced by 15%), decreased apoptotic cardiomyocytes (TUNEL-positive cells reduced by 40%), and suppressed cleaved caspase-3 and PARP1 expression. Oxidative stress markers (O2-, nitrotyrosine) were reduced by 30-40% in infarcted myocardium. |
IC 50
PARP-1
storage
+4°C
References
[1] D DAVAR. Role of PARP inhibitors in cancer biology and therapy.[J]. Current medicinal chemistry, 2012, 19 23: 3907-3921. DOI: 10.2174/092986712802002464
[2] MARLENE T MATHEWS Bradford C B. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2.[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28 4: 711-717. DOI: 10.1161/atvbaha.107.156406
[3] GABRIELE COSTANTINO. Modeling of Poly(ADP-ribose)polymerase (PARP) Inhibitors. Docking of Ligands and Quantitative Structure?Activity Relationship Analysis[J]. Journal of Medicinal Chemistry, 2001, 44 23: 3786-3794. DOI: 10.1021/jm010116l
[4] TOBIAS ELTZE. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.[J]. ACS Applied Electronic Materials, 2008: 1587-1598. DOI: 10.1124/mol.108.048751
[5] ELENA FONFRIA. TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase[J]. British Journal of Pharmacology, 2009, 143 1: 186-192. DOI: 10.1038/sj.bjp.0705914
[6] L. GIOVANNELLI. Comet Assay as a Novel Approach for Studying DNA Damage in Focal Cerebral Ischemia: Differential Effects of NMDA Receptor Antagonists and Poly(ADP-Ribose) Polymerase Inhibitors[J]. Journal of Cerebral Blood Flow & Metabolism, 2002, 39 1 1: 697-704. DOI: 10.1097/00004647-200206000-00008
DPQSupplier
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- 13816107857
- sales@fortunechem-sh.com
- Tel
- 021-021-33632979 15002134094
- marketing@targetmol.com
- Tel
- 400-1166-196 13458535857
- cdhxsj@163.com
- Tel
- 021-61415566 800-8193336
- orderCN@merckgroup.com
DPQ(129075-73-6)Related Product Information
- 4-AMINO-1,8-NAPHTHALIMIDE
- 3-Aminobenzamide
- NU1025
- DMEM/F12 medium
- DMEM medium
- 4-Hydroxyquinazoline
- Rucaparib
- ABT-888
- 1,5-ISOQUINOLINEDIOL
- 1(2H)-Isoquinolinone, 5-aMino-, Monohydrochloride
- 5-Benzoyloxy-1(2H)-isoquinolinone
- 3-(4-CHLORO-PHENYL)-QUINOXALINE-5-CARBOXYLIC ACID AMIDE
- TIQ-A
- 5-METHOXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE
- DPQ
- 5-HYDROXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE
- 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-5-OL
- DULBECCO'S MODIFIED EAGLE'S MEDIUM W/L-&